Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates

Transfusion

Volumn 45, Issue 6, 2005, Pages 911-919

  Perez Pujol, S ^b   Tonda, R ^b   Lozano, M ^b   Fuste, B ^b   Lopez Vilchez, I ^b   Galan, Ana M ^a   Li, J ^b   Goodrich, R ^b   Escolar, G ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5A; CD36 ANTIGEN; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRONECTIN; GLYCOPROTEIN IB ALPHA; LIPOCORTIN 5; MEMBRANE PROTEIN; PADGEM PROTEIN; RIBOFLAVIN; THROMBOCYTE CONCENTRATE; VON WILLEBRAND FACTOR;

APHERESIS; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DEVICE; DISEASE TRANSMISSION; EVALUATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LOW TEMPERATURE; MEDICAL TECHNOLOGY; PATHOGEN REDUCTION TECHNOLOGY; PRIMARY PREVENTION; PROTEIN BINDING; PROTEIN EXPRESSION; THROMBOCYTE ADHESION; THROMBOCYTE FUNCTION; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; ULTRAVIOLET IRRADIATION;

ANNEXIN A5; ANTIGENS, CD; BLOOD PLATELETS; BLOOD PRESERVATION; FIBRINOGEN; FIBRONECTINS; FLOW CYTOMETRY; HUMANS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; P-SELECTIN; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET MEMBRANE GLYCOPROTEIN IIB; PLATELET TRANSFUSION; PLATELETPHERESIS; RIBOFLAVIN; TEMPERATURE; TIME FACTORS; ULTRAVIOLET RAYS; VON WILLEBRAND FACTOR;

EID: 20444390924     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2005.04350.x     Document Type: Article

References (40)

1. Sakariassen KS, Bolhuis PA, Sixma JJ. Human platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium. Nature 1979;279:636-8.
2. Nieuwenhuis HK, Sakariassen KS, Houdijk WP, et al. Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood 1986;68:692-5.
3. Kehrel B, Wierwille S, Clemetson KJ, et al. Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood 1998;91:491-9.
4. Sakariassen KS, Nievelstein PF, Coller BS, et al. The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol 1986;63:681-91.
5. Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 1999;94:172-8.
6. Bevers EM, Comfurius P, Zwaal RF. Platelet procoagulant activity: phyisiological significance and mechanims of exposure. Blood Rev 1991;5:146-54.
7. Weiss HJ, Hoffmann T, Turitto VT, et al. Further studies on the presence of functional tissue factor activity on the subendothelium of normal human and rabbit arteries. Thromb Res 1994;73:313-26.
8. Hoffman M, Monroe DM, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998;9:S61-S65.
9. Bessos H, Atkinson A, McGill A, et al. Apheresis platelet concentrates: correlation of day one levels of in vitro quality markers with corresponding levels on days two to five of storage. Thromb Res 1996;84:367-72.
10. Metcalfe P, Williamson LM, Reutelingsperger CP, et al. Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haematol 1997;98:86-95.
11. Lozano M, Estebanell E, Cid J, et al. Platelet concentrates prepared and stored under currently optimal conditions: minor impact on platelet adhesive and cohesive functions after storage. Transfusion 1999;39:951-9.
12. Estebanell E, Diaz-Ricart M, Escolar G. Alterations in cytoskeletal organizatrion and tyrosine phosphorylation in PCs prepared by the BC method. Transfusion 2000;40:535-42.
13. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004;44:877-85.
14. Li J, De Korte D, Woolum MD, et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004;87:82-90.
15. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2004;44(Suppl):16.
16. Lozano M, Escolar G, White JG, et al. Redistribution of membrane glycoproteins in platelets activated under flow conditions. Blood Coagul Fibrinolysis 1996;7:214-7.
17. Escolar G, Lozano M, DiazRicart M, et al. Modifications in accessibility of membrane glycoproteins, binding of specific ligands and coagulation factor V during the activation of platelets in blood emerging from bleeding time wounds. Am J Hematol 1999;60:260-7.
18. Galan AM, Hernandez MR, Bozzo J, et al. Preparations of synthetic phospholipids promote procoagulant activity on damaged vessels: studies under flow conditions. Transfusion 1998;38:1004-10.
19. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973;5:167-79.
20. Escolar G, Bastida E, Ordinas A, et al. Interaction of platelets with subendothelium in humans treated with aspirin and dipyridamole alone or in combination. Thromb Res 1985;40:419-24.
21. Escolar G, Mazzara R, Castillo R, et al. The role of the Baumgartner technique in transfusion medicine: research and clinical applications. Transfusion 1994;34:542-9.
22. Li J, De Korte D, Woolum M, et al. Performance of the Mirasol PRT system with buffy coat platelet and apheresis platelet concentrates. Vox Sang 2004;87:S17-92.
23. Eriksson L, Kristensen J, Olsson K, et al. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Vox Sang 1996;70:69-75.
24. Hagberg IA, Akkok CA, Lyberg T, et al. Apheresis-induced platelet activation: comparison of three types of cell separators. Transfusion 2000;40:182-92.
25. Rinder HM, Snyder EL, Bonan JL, et al. Activation in stored platelet concentrates-correlation between membrane expression of P-selectin, glycoprotein IIb/IIIa, and beta-thromboglobulin release. Transfusion 1993;33:25-9.
26. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
27. Janetzko K, Lin L, Eichler H, et al. Implementation of the INTERCEPT blood system for platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004;86:239-45.
28. Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004;44:320-9.
29. Xiao HY, Matsubayashi H, Bonderman DP, et al. Generation of annexin V-positive platelets and shedding of microparticles with stimulus-dependent procoagulant activity during storage of platelets at 4°C. Transfusion 2000;40:420-7.
30. Thiagarajan P, Tait JF. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J Biol Chem 1991;266:24302-7.
31. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998;31:1-9.
32. Dachary-Prigent J, Freyssinet JM, Pasquet JM, Carron JC, Nurden AT. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood 1993;81:2554-65.
33. Diaz C, Schroit AJ. Role of translocases in the generation of phosphatidylserine asymetry. J Membr Biol 1996;151:1-9.
34. Li J, Xa Y, Bertino AM, et al. The mechanism of apoptosis in human platelets during storage. Transfusion 2000;40:1320-9.
35. Hernandez MR, Bozzo J, Mazzara R, et al. Platelet concentrates promote procoagulant activity: evidence from experimental studies using a perfusion technique. Transfusion 1995;35:660-5.
36. Escohr G, Galan AM, Mazzara R, et al. Measurement of platelet interactions with subendothelial substrata: relevance to transfusion medicine. Transfus Med Rev 2001;15:144-56.
37. McGill M, Brindley DC. Effects of storage on platelet reactivity to arterial subendothelium during blood flow. J Lab Clin Med 1979;94:370-80.
38. Boomgaard MN, Gouwerok CW, Homburg CH, et al. The platelet adhesion capacity to subendothelial matrix and collagen in a flow model during storage of platelet concentrates for 7 days. Thromb Haemost 1994;72:611-6.
39. Alemany M, Hernandez MR, Bozzo J, et al. In vitro evaluation of the hemostatic effectiveness of non-viable platelet preparations: studies with frozen-thawed, sonicated or lyophilized platelets. Vox Sang 1997;73:36-42.
40. Escolar G, Mazzara R, White JG, et al. Contribution of perfusion techniques to the evaluation of the hemostatic effectiveness of platelet concentrates. Blood Cells 1992;18:403-15.